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M. Carter9, Y. Lou1, R. Nicolson10, S. Georgiades11, P. Szatmari12,13, E. Anagnostou14,15, S. W. Scherer1,4,7,
S. Choufani1, M. Brudno1,2,16 and R. Weksberg1,3,4,15,17*

Abstract
Background: Autism spectrum disorder (ASD) is a common and etiologically heterogeneous neurodevelopmental
disorder. Although many genetic causes have been identified (> 200 ASD-risk genes), no single gene variant
accounts for > 1% of all ASD cases. A role for epigenetic mechanisms in ASD etiology is supported by the fact that
many ASD-risk genes function as epigenetic regulators and evidence that epigenetic dysregulation can interrupt
normal brain development. Gene-specific DNAm profiles have been shown to assist in the interpretation of variants
of unknown significance. Therefore, we investigated the epigenome in patients with ASD or two of the most
common genomic variants conferring increased risk for ASD. Genome-wide DNA methylation (DNAm) was assessed
using the Illumina Infinium HumanMethylation450 and MethylationEPIC arrays in blood from individuals with ASD
of heterogeneous, undefined etiology (n = 52), and individuals with 16p11.2 deletions (16p11.2del, n = 9) or
pathogenic variants in the chromatin modifier CHD8 (CHD8+/−, n = 7).
Results: DNAm patterns did not clearly distinguish heterogeneous ASD cases from controls. However, the
homogeneous genetically-defined 16p11.2del and CHD8+/− subgroups each exhibited unique DNAm signatures
that distinguished 16p11.2del or CHD8+/− individuals from each other and from heterogeneous ASD and control
groups with high sensitivity and specificity. These signatures also classified additional 16p11.2del (n = 9) and CHD8
(n = 13) variants as pathogenic or benign. Our findings that DNAm alterations in each signature target unique
genes in relevant biological pathways including neural development support their functional relevance.
Furthermore, genes identified in our CHD8+/− DNAm signature in blood overlapped differentially expressed genes
in CHD8+/− human-induced pluripotent cell-derived neurons and cerebral organoids from independent studies.
Conclusions: DNAm signatures can provide clinical utility complementary to next-generation sequencing in the
interpretation of variants of unknown significance. Our study constitutes a novel approach for ASD risk-associated
molecular classification that elucidates the vital cross-talk between genetics and epigenetics in the etiology of ASD.
Keywords: Epigenetics, DNA methylation, Autism spectrum disorder, Genomic variants, Genetic stratification,
Heterogeneity
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Introduction
Autism spectrum disorder (ASD) comprises a group of
complex neurodevelopmental conditions, diagnosed in 1 of
68 (1.4%) individuals in the general population [1]. Significant etiologic heterogeneity is implied by the variable penetrance of a large number of genetic causes involving > 200
ASD-risk loci (i.e., single genes, copy number variants
[CNVs]) that have been identified in ~ 25–40% of individuals with ASD [2–6]; no single genetic cause accounts for >
1% of ASD cases [6–9]. Given that ASD is a multifactorial
disorder, the expectation is that the combined contribution
of multiple etiologic factors will determine an individual’s
risk, whereby once a threshold is reached, the clinical features expressed will support a diagnosis of ASD [10]. Other
etiologic factors currently implicated in ASD etiology
include environmental and epigenetic mechanisms. Many
ASD-risk genes are “epigenes” encoding proteins that function as epigenetic regulators, i.e., chromatin remodelers
and transcriptional regulators, supporting a role for epigenetic dysregulation in ASD etiology [4, 11–13]. Epigenetic
marks such as DNA methylation (DNAm) are precisely
programmed spatially and temporally during normal development. DNAm alterations caused by genetic and/or environmental factors could negatively impact biological
pathways important for normal brain development.
DNAm is one of the most stable and commonly assessed
epigenetic marks. DNAm results from the transfer of a methyl group to cytosine in a CpG dinucleotide, catalyzed by
DNA methyltransferase enzymes. These modifications are
established and maintained through cell division. We, and
others, have shown that there is crosstalk between histone
modifications and CpG methylation in DNA; that is, cells
from individuals with variants in some epigenes demonstrate functionally relevant genome-wide DNAm alterations that constitute gene-specific signatures. DNAm
signatures have been previously identified in peripheral
blood for disorders caused by pathogenic variants in
epigenes that are associated with neurodevelopmental outcomes including both non-syndromic ASD and syndromic
ASD/intellectual disability (ID) (e.g., NSD1 variants associated with Sotos syndrome, CHD7 variants associated with
CHARGE syndrome) [14–23]. We have shown that these
DNAm signatures represent a promising avenue to improve an increasingly challenging issue in clinical diagnostics. While advancing clinical diagnostics, next-generation
sequencing (NGS) has magnified one of the most significant challenges of DNA sequencing-based testing, namely
the interpretation of variants of unknown significance
(VUS). VUS are increasingly detected as the utilization of
diagnostic sequencing expands in both the clinical and research arenas, also true in the context of ASD. Specifically,
DNAm signatures are proving to be effective in the functional classification of VUS [14, 15, 18, 19]. A limited number of studies have examined the potential for developing
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ASD-specific DNAm biomarkers [24–29]. They report
inconsistent differences at a variety of genomic sites in peripheral blood [29], brain [26, 27, 30], buccal epithelium
[24], and sperm [31]. These studies are limited by small
sample sizes and modest DNAm differences between ASD
cases and controls likely due not only to inter-tissue and
cell type variability, but also more importantly to heterogeneity of DNAm alterations in individuals with ASD with
unselected etiologies.
We hypothesized that epigenetic alterations contribute
to the molecular etiology of ASD and that the discovery of
such epigenetic alterations could be enhanced by genetic
stratification of ASD cases. More specifically, we expected
that individuals with ASD and variants in specific epigenes
would display distinct DNAm signatures, as previously
demonstrated for other human disorders caused by variants in epigenes or CNVs overlapping epigenes [14–17,
20, 21, 23]. We also expect that we will be able to use the
DNAm signatures to classify additional cases with variants
in the specific epigenes or CNVs overlapping epigenes as
pathogenic or benign. We therefore undertook several
analyses comparing ASD cases and controls. First, we
compared genome-wide DNAm in blood from individuals
with ASD of undefined etiology (i.e., heterogeneous ASD)
to controls. Next, we compared controls to cases with two
of the most common genomic variants associated with an
increased risk for ASD.
The first genetically homogeneous subgroup comprised
individuals with 600 kb deletions in 16p11.2, a CNV
known to confer ASD susceptibility (16p11.2del; OMIM#
611913). Individuals with 16p11.2del have a variable
phenotype; 20–30% receive a diagnosis of ASD, although
the majority of these individuals have behavioral/neurocognitive ASD features [32–34]. The HIRA-interacting
protein 3 gene (HIRIP3), located in the 16p11.2del region,
is known to be involved in regulating histone metabolism
and chromatin function [35], but the full impact of
16p11.2 deletions on epigenetic dysregulation has yet to be
elucidated. The second genetically homogeneous subgroup
comprised individuals with known pathogenic variants in
the chromodomain helicase DNA-binding protein 8 gene
(CHD8+/−; OMIM# 615032). More than 85% of individuals
with CHD8 variants have ASD, as well as morphological
anomalies and other neurodevelopmental features [4, 36,
37]. CHD8 is known to function as an epigenetic regulator,
playing a critical role in transcriptional repression through
chromatin remodeling [38].
Our results demonstrate that genetically defined subgroups of cases with genomic aberrations at ASD-risk
loci involving epigenes have highly sensitive and specific
DNAm signatures that distinguish them from heterogeneous ASD cases and controls. We also show that these
DNAm signatures identify genomic targets that may
contribute to the etiology of specific genetic subgroups
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of ASD. The differentially methylated gene targets of our
DNAm signatures function in biological pathways that
are relevant to proposed pathophysiological mechanisms
underlying ASD, highlighting the biological significance
of our DNAm signatures. Lastly, we show that our
DNAm signatures have the potential to be used as a
complementary molecular diagnostic tool to help interpret the pathogenicity of VUS, demonstrating their functional utility and potential for clinical application.

Methods and materials
Participants

The ASD group consisted of an etiologically undefined,
heterogeneous sample of individuals (heterogeneous
ASD; n = 52) not selected for any known genomic features, for whom deep clinical phenotyping and whole
genome/exome sequencing data were available through
the Province of Ontario Neurodevelopmental Disorders
(POND) Network and the Simons Simplex Collection
(SSC) (Additional file 3: Table S1). All neurotypical control samples were selected from a collection available in
our laboratory (Additional file 3: Table S1). The majority
of individuals included in this study are of Caucasian
descent; however, ethnicity data were not available for all
individuals included. Some individuals in the control
group received formal cognitive/behavioral assessments
(Dr. Greg Hanna, University of Michigan); others were
recruited using physician/parental screening questionnaires. Our 16p11.2del training case group consisted of
DNA samples from the blood of individuals with confirmed typical 600 kb deletions in 16p11.2 (16p11.2del;
chr16: 29.5–30.1 Mb) that were used for signature derivation (n = 9; 3 with ASD diagnosis) (Table 1). The
16p11.2 test case group consisted of samples from additional individuals with 16p11.2del variants and were
used to test the signature (classification) (n = 9; 4 with
ASD diagnosis) (Hospital for Sick Children [SickKids],
POND; Table 3). Our CHD8+/− training case group consisted of DNA samples from the blood of individuals with
confirmed de novo CHD8 pathogenic variants (CHD8+/−; n
= 7, all with ASD diagnosis) obtained from SSC (Table 2)
for signature derivation. The CHD8+/− test case group consisted of additional CHD8 sequence variants (n = 13; 12
with an ASD diagnosis) for classification. These were obtained from SSC, SickKids, The University of Alberta (Dr.
Oana Caluseriu), and the Children’s Hospital of Eastern
Ontario (CHEO; Dr. Melissa Carter) (Table 3).
DNAm analysis

DNA was extracted from whole blood for all cases and
controls using standard techniques. Extracted DNA was
sodium bisulfite converted using the Qiagen EZ DNA
Methylation kit (Qiagen, Valencia, CA), according to the
manufacturer’s protocol. All DNA samples were
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processed according to the manufacturer’s protocol for
DNAm analysis using either the Illumina Infinium
HumanMethylation450 BeadChip array (450K array) or
the Illumina MethylationEPIC (EPIC array; an additional
set of CHD8 test case sequence variants only) at The
Centre for Applied Genomics (SickKids). The distribution of the samples on the arrays was randomized for all
cases and controls and for age and sex variables. The
450K array covers > 485,000 individual CpG sites,
whereas the EPIC array covers > 850,000 individual CpG
sites genome-wide at single-nucleotide resolution,
encompassing > 99% of RefSeq genes and > 96% of annotated CpG islands.
Statistical analysis: DNAm signatures for 16p11.2del and
CHD8+/−

Raw genome-wide DNAm data were analyzed using our
laboratory’s bioinformatics pipeline employing hierarchical
clustering, principal component analysis (PCA) and nonparametric statistical comparisons [15] (Additional file 2:
Figure S1). Raw data normalization and pre-processing
quality control steps were performed to ensure that only
high-quality data were included for group comparisons to
identify DNAm differences. Illumina Genome Studio software was used to normalize data (IDAT files) using background subtraction and control normalization to generate
methylation values (Beta [β]-values). Before analysis, data
for probes located on sex chromosomes, autosomal probes
that cross-react with sex chromosome probes, non-specific
probes, and probes targeting CpG sites within 5 bp of a
SNP with a minor allele frequency > 1% were removed [16]
(Additional file 3: Table S2). For signature derivation, batch
correction by mean-centering was applied in Qlucore
Omics Explorer (QOE, www.qlucore.com) to the comparison of 16p11.2del cases to age- (Mann-Whitney U test, p >
0.05), sex-matched (Chi-square (χ2) test, p > 0.05) controls
before performing group comparisons; all other casecontrol groups were run in single batches. Since there were
differences in the composition of age and sex in each group
(ASD, 16p11.2del, and CHD8+/−), each training group was
compared to a different set of age- and sex-matched controls. The topmost variable probes were used for group
comparisons (i.e., least variable CpG sites across the dataset
were removed using the QOE 3.2 “filtering by variance”
tool), a commonly used prioritization step that increases
statistical power while being blinded to group assignment
[39]. For example, a variance-filtering parameter “var =
0.02” removes sites with a standard deviation < 2% of the
maximal standard deviation. The number of sites retained
depended on the specific samples included in each paired
group comparison. The derivation of DNAm signatures
employed the use of limma regression modeling to account
for covariates and the Mann-Whitney U test to account for
possible non-parametric effects. Significantly differentially
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Table 1 Demographic and deletion information for 16p11.2del training signature cases and age-, sex-matched controls
Sample ID

Sex

Age (years)

ASD status

16p11.2del (600 kb region) coordinates

Deletion size (kb)

Inheritance

435

M

12

Unknown

29,656,657–30,190,593

534

Unknown

516

M

7

Unknown

29,656,657–30,190,593

534

Unknown

639

F

13

Unknown

29,592,751–30,190,593

598

Unknown

797

M

7

Unknown

29,590,493–30,190,593

600

Unknown

871

M

10

Unknown

29,590,493–30,190,593

600

Unknown

293

M

5

Unknown

29,567,295–30,178,406

611

Unknown

3-0269-000

M

4

ASD

29,567,309–30,177,807

610

Maternal

1-0019-004

M

7.5

ASD

29,652,799–30,199,507

547

De novo

7-0229-003

M

11.5

ASD

29,567,295–30,177,916

611

Unknown

EP15W

M

13

Control

EP16W

F

2

Control

EP17W

F

4

Control

EP1W

F

8

Control

EP22W

M

4

Control

EP2W

F

10

Control

EP3W

F

13

Control

EP4W

M

13

Control

EP5W

F

8

Control

EP6W

M

13

Control

EP7W

M

9

Control

EP8W

M

8

Control

EP9W

M

11

Control

EP51

M

12

Control

EP60W

M

12

Control

460/2048

M

11.5

Control

EP32W

M

6

Control

EP45W

M

10

Control

EP59W

M

6

Control

EP57W

M

7

Control

CT0011-003

M

4

Control

MK-311/1601

M

10

Control

KA-352/1734

M

7

Control

Mean age 16p11.2del 8.556 ± 3.196
Mean age Control 8.761 ± 3.35
16p11.2.del M, F 8, 1
Control M, F 17, 6

methylated sites between signature training cases and controls were first identified using limma regression, using
age, sex, and estimated cell type proportion (minfi) as
covariates, with a Benjamini-Hochberg adjusted p value (qvalue) < 0.05 and requiring a |Δβ| ≥ 0.05 (at least 5%
methylation difference). We then identified significant
differentially methylated sites independently using the nonparametric Mann-Whitney U test with a BenjaminiHochberg adjusted p value (q-value) < 0.05. Optimal qvalue and DNAm effect size (Δβ) thresholds were selected

using volcano plots (Additional file 2: Figures S2 and S3).
To be conservative, the final DNAm signature CpG lists
were defined as the overlap among the results of limma
regression, the Mann-Whitney U test, and the effect-size
requirement.
In addition to incorporating blood cell type proportions
as covariates in the derivation of our DNAm signatures
(Additional file 1) [40], DNAm data for different blood
cell-subtypes [41] were also used to directly ensure that
differential methylation at signature sites was not
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Table 2 Demographic and variant information for CHD8+/− training signature cases and age-, sex-matched controls
Sample ID

Sex

Age (years)

ASD status

Nucleotide change

Amino acid change

Exon

Inheritance

11654.p1

F

12.5

ASD

c.3517 A>G

p.Arg1173Gly

16

De novo

12714.p1

M

5

ASD

c.185C>G

p.Ser62X

1

De novo

12752.p1

F

8

ASD

c.6359_6360del

p.Leu2120ProfsX

32

De novo

12991.p1

M

16

ASD

c.6307_6308del

p.Glu2103ArgfsX

31

De novo

13844.p1

M

5

ASD

c.3712C>T

p.Gln1238X

17

De novo

14016.p1

M

14

ASD

c.4009C>T

p.Arg1337X

19

De novo

14233.p1

M

10

ASD

c.7113_7114del

p.Asn2371LysfsX2

36

De novo

EP48W

F

11

Control

EP58W

M

15

Control

EP41W

M

16

Control

EH-268 W

F

6

Control

JS-265 W

M

16

Control

EP34W

F

13

Control

TG-278 W

M

13

Control

TB-342/1706

M

16

Control

EP43W

F

7

Control

EP32W

M

6

Control

JL-137/1362

M

14

Control

EP45W

M

10

Control

EP59W

M

6

Control

EP57W

M

7

Control

CT0009-003

M

8

Control

CT0011-003

M

4

Control

MK-311/1601

M

10

Control

EP39W

F

13

Control

EP42W

F

8

Control

KA-352/1734

M

7

Control

MM-119/1567

M

10

Control

+/−

Mean age CHD8 10.07 ± 4.325
Mean age Control 10.29 ± 3.836
CHD8+/− M, F 5, 2
Control M, F 15, 6

confounded by differences in blood cell-type proportions,
as similarly applied in Ref. [14, 15] (Supplementary Information; Additional file 2: Figures S5 and S6).
Comparison of differentially methylated CpG sites across
DNAm signatures and differentially methylated regions
(DMRs)

To detect consistent patterns of DNAm alterations from
our DNAm signatures, we used an additional method to
identify significantly differentially methylated regions
(DMRs) overlapping and extending from individual CpG
sites contained in each respective DNAm signature. We
used the bump hunting method [42], which strengthens
the detection of regional differences by combining differential methylation patterns across neighboring CpG sites

[43]. The analysis detected DMRs that comprise CpGs
with |Δβ| ≥ 5% between cases and controls as candidates
for the DMRs, with gaps ≤ 500 bp between neighboring
CpGs. Statistical significance was established using 1000
randomized bootstrap iterations to account for
confounders, as recommended in the Bioconductor
bumphunter package documentation. The resulting
DMRs were post-filtered to retain only those with p
values < 0.05 and average methylation differences
|Δβ| ≥ 5% across the DMR. To further enhance robustness and improve stringency, we also required
these DMRs to (1) comprise at least three consecutive
CpGs and (2) include at least one CpG from the
DNAm signatures previously derived for either
16p11.2del or CHD8+/−, as described above
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Table 3 Variant details and respective classification scores for 16p11.2del CNV and CHD8 test cases
Sample ID

Sex Age (years) 16p11.2del coordinates
(size in kb)

Diagnostic classification for
Inheritance
16p11.2 typical deletion
(pathogenic, benign, variant
of unknown significance [VUS])

348

M

0.25

29,590,493–30,190,593 (600)

Pathogenic

Unknown

Unknown

0.11505

228

M

0.4

29,590,493–30,190,593 (600)

Pathogenic

Unknown

Unknown

0.12668

875

F

4

29,656,657–30,190,593 (534)

Pathogenic

Unknown

Unknown

0.03073

172

F

6

29,590,493–30,190,593 (600)

Pathogenic

Unknown

Unknown

0.04668

292

M

0.25

29,500,252–30,098,094 (598)

Pathogenic

Unknown

Unknown

0.13978

2-0088-003

F

12

29,652,799–30,199,507 (547)

Pathogenic (MOSAIC)

De novo

ASD

-0.00441

3-0406-000

M

1.2

29,581,764–30,199,579 (618)

Pathogenic

Unknown

ASD

0.07735

6-0196-03

M

Unknown

29,500,084–30,098,210 (598)

Pathogenic

Unknown

ASD

0.04815

1-0616-003

M

7.5

28,751,255–28,952,351 (201)

Not determined*

Maternal

ASD

− 0.11936

Sample ID

Sex Age (years) CHD8 variant nucleotide
change; amino acid change
(Exon #)

14406.p1

M

13

c.7493_7495del; p.His2498del (37) VUS

1-0494-003

M

4.75

c.2219A>G; p.Asn740Ser (9)

Benign

2-1228-003

F

4.5

c.6841C>G; p.Pro2281Ala (34)

Benign

1-0277-003

M

Unknown

c.6565G>A; p.Gly2189Arg (33)

Benign

1-0507-003

F

14

c.3940G>A; p.Ala1314Thr (19)

Benign

Diagnostic classification
Inheritance
(pathogenic, benign, variant
of unknown significance [VUS])

ASD status 16p11.2del score

ASD status CHD8+/− score

ASD

− 0.03482

Paternal

ASD

− 0.04451

Paternal

ASD

− 0.04178

Maternal

ASD

− 0.03065

Maternal

ASD

− 0.05507

De novo

7-0167-003

M

4

c.7499A>C; p.His2500Pro (37)

Benign

Unknown

ASD

− 0.05984

1-0559-003

M

7.7

c.6148dupA; p.Thr2050fs (31)

Pathogenic

De novo

ASD

0.0437

CHD8-V1

M

10

c.4215G>T; Synonymous (21)

VUS

Paternal

ASD

− 0.04478

CHD8-V2 (father
of CHD8-V1)

M

40

c.4215G>T; Synonymous (21)

VUS

Not applicable Unaffected − 0.04332

CHD8-V3**

M

6.5

c.6649C>T, p.Arg2217* (33)

Pathogenic

Paternal

ASD

0.04616

CHD8-V4 (sibling M
of CHD8-V3)**

14

c.6649C>T, p.Arg2217* (33)

Pathogenic

Paternal

ASD

0.03631

DW0013**

M

13.5

c.6947delC, p.Pro2316Leufs*39
(35)

Likely pathogenic

Unknown

ASD

0.05183

EX0070-W**

M

6.75

c.4327C>T, p.Arg1443Cys (21)

VUS

Paternal

ASD

− 0.04131

*Deletion encompassing SH2B1 gene, not overlapping 16p11.2del typical deletion region
**Test case data are from EPIC array, classified using 93 probes overlapping 450K and EPIC arrays from CHD8+/− signature

(Additional file 3: Tables S3 and S4). DMRs are presented using visualization methods adapted from
DMRcate software (Additional file 2: Figure S4) [44].
Testing sensitivity and specificity of 16p11.2del and
CHD8+/− DNAm signatures using independent test cases
and controls

The 16p11.2del and CHD8+/−-specific DNAm signatures
were used to build predictive models to functionally
classify independent 16p11.2del CNVs and CHD8 test
case variants as well as unrelated controls as pathogenic
or benign. These include variants that were reported as
pathogenic, benign, or of unknown significance (VUS).
To evaluate the predictive models, we used independent,
unrelated test cases to determine sensitivity and controls
to determine specificity. We evaluated sensitivity on a

test cohort of 16p11.2del CNV (n = 9) and CHD8 variants (n = 13), independent of the training cases. Four of
the CHD8 variant test cases were run on the EPIC array.
These test cases were classified using the 450K-derived
CHD8+/− DNAm signature probes that overlapped with
those on the EPIC array (92/103 signature sites). To
evaluate the specificity of the DNAm classification signatures, we tested the DNAm signatures on a test set of
control 450K array data (n = 162, described in further
detail below), independent of those used in the signature
derivation. To confirm that the two models did not generate overlapping predictions, we applied the 16p11.2del
predictive model to the CHD8+/− cohort, and conversely
the CHD8+/− predictive model to the 16p11.2del cohort.
For each set of training cases and controls used to derive
a signature, a reference DNAm profile was generated
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across the signature-specific CpGs, by computing median DNAm for each CpG site over all samples in the
selected cohort (separately for cases and controls) [15].
Classification scores for additional variant test cases and
control samples (Table 2; Additional file 3: Table S5) and
corresponding classification plots were generated by
comparing the correlation of each sample to the two respective reference profiles (corresponding to signature
training cases and to controls). For example, blood samples
with positive 16p11.2del scores will cluster more closely
with the 16p11.2del reference profile, whereas samples with
negative 16p11.2del scores will cluster more closely with
the control reference profile.

Genomic distribution of DNAm signature CpG sites

The genomic distribution of CpG sites contained in each
DNAm signature was compared with that of the respective variance-filtered datasets to identify signaturespecific regions of enrichment or depletion using a
hypergeometric test (implemented in R).

Additional datasets used for investigating functional
significance of DNAm signatures

For additional specificity analysis, we used an independent publicly available set of 450K DNAm data derived
from whole blood of control individuals (n = 162) with
known ages < 50 years (mean 35.8 years) (Gene Expression Omnibus (GEO) Database; www.ncbi.nlm.nih.gov/
geo/) (Additional file 3: Table S5). We did not expect
control individuals to have 16p11.2del or CHD8 variants
as these genomic variants are present in < 0.04% of the
general population [45–47].
To determine the biological relevance of our DNAm
signatures, we compared our differentially methylated
genes with known ASD-risk genes (SFARI Gene
[https://gene.sfari.org/]). To examine cross-tissue and
functional relevance of our CHD8+/− signature, we
compared the list of differentially methylated genes to
those differentially expressed in an independent study
using an engineered hemizygous deletion of CHD8
(CHD8+/−; using CRISPR/Cas9) in human induced
pluripotent stem cell (iPSC)-derived neuronal precursor
cells (NPCs), differentiated neurons [48], and cerebral
organoids [49].
We used GREAT 3.0.0 (http://great.stanford.edu; up to
1 Mbp extension from the nearest genes) to identify
functional enrichment of biological pathways in the
differentially methylated genes of each DNAm signature
in the context of wider genomic regions. Enrichment of
each set of signature CpGs was defined against the background set of all probes that remained in the data after
filtering by variance.
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DNAm validation by targeted sodium bisulfite
pyrosequencing

Specific differentially methylated sites found in each respective DNAm signature for 16p11.2del or CHD8+/−
training signature cases and their age-, sex-matched controls were validated on sodium bisulfite-converted DNA
using targeted pyrosequencing assays. These assays were
designed using Qiagen Assay Design Software v2.0 to target specific CpGs identified by the microarray experiment
as well as adjacent sites (Additional file 1). Selected sites
are significantly differentially methylated in both the
respective DNAm signatures and DMRs (Additional file 2:
Figure S4; Additional file 3: Tables S3 and S4). Pyrosequencing was performed using the PyroMark Q24 system
and Pyrosequencing Gold Reagents (Qiagen). Testing for a
statistical difference between groups was performed using
a Mann-Whitney U test (p < 0.05).

Results
DNAm does not distinguish heterogeneous ASD cases
from controls

DNAm profiles of the heterogeneous ASD group (n = 52)
were compared with age-, sex-matched controls (n = 30)
at 40550 sites following filtering by variance. Neither
limma nor Mann-Whitney U analyses identified any
significant sites after Benjamini-Hochberg correction for
multiple testing (all q > 0.05). Only 22 sites (16 (72.3%)
hypomethylated, 6 (27.3%) hypermethylated) passed our
criteria of an unadjusted p < 0.001 and |Δβ| > 5%. At this
set of sites, no clear distinction between the ASD cases
and controls could be made by either hierarchical clustering or principal components analysis (PCA), and thus no
DNAm signature was identified.
Given that the genetically homogeneous groups,
16p11.2del and CHD8+/−, were selected for their potential
for elucidating epigenetic dysregulation, we assessed
whether these groups could be distinguished epigenetically
from the heterogeneous ASD group and controls. The
16p11.2del and CHD8+/− cases were therefore classified at
the 22 sites where putative ASD differences were detected
(p < 0.001, |Δβ| ≥ 5%). No distinct clustering of either
group was apparent, i.e., all 16p11.2del and CHD8+/− cases
were mixed with both ASD cases and controls (Fig. 1).
These data suggested that any potential 16p11.2del- or
CHD8+/−-specific DNAm alterations were obscured by the
presence of other heterogeneous ASD cases. Therefore, we
focused next on the potential discovery of specific DNAm
signatures, contingent on direct comparisons of genetically
homogeneous ASD-risk groups with controls.
Identification of a 16p11.2del-specific DNAm signature

Following filtering by variance (24,009 sites remaining),
comparison of the DNAm data from the training
16p11.2del group (n = 9; Table 1) to our age-, sex-matched
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Fig. 1 Whole blood DNAm comparison between heterogeneous ASD group (n = 52) and age-, sex-matched controls (n = 30). Following filtering
by variance (40,550 sites), limma regression and Mann-Whitney U comparison, no CpG sites meet significance criteria of q ≤ 0.05. The 22 sites
shown at uncorrected p < 0.001, |Δβ| ≥ 5% do not distinguish clearly between ASD cases and controls. Hierarchical clustering (Euclidian) and
principal component analysis (PCA, first 3 principal components labeled) plot show that 16p11.2del (purple) and CHD8+/− (orange) cases are
mixed with both heterogeneous ASD cases (gray) and controls (green). Data are normalized for visualization (mean = 0, variance = 1). In heat
map, yellow represents high methylation and blue represents low methylation

controls (n = 23) showed that our stratification approach
allowed cases to be distinguished from controls based on
DNAm differences at specific genomic sites. These distinctions are demonstrated by both hierarchical clustering and
PCA plot (Fig. 2a). One hundred fifteen sites (77 (67%)
hypomethylated, 38 (33%) hypermethylated) distributed
across the genome passed our criteria of q < 0.05 and |Δβ|
≥ 5% (|Δβ| range 8–23%). This set of sites constitutes the
16p11.2del DNAm signature (Additional file 2: Figure S2;
Additional file 3: Table S6); none of these 115 sites are contained in the 16p11.2del region.
Identification of a CHD8+/−-specific DNAm signature

We compared DNAm data from a group of individuals
with known pathogenic CHD8 variants (n = 7) (Table 2)
to age-, sex-matched controls (n = 21). Following filtering by variance (87,662 sites remaining), 422 sites (392

(92.9%) hypomethylated, 30 (7.1%) hypermethylated) distributed across the genome passed our criteria of q <
0.05, |Δβ| ≥ 5% (|Δβ| range 5–54%) (Additional file 3:
Table S7) and distinguished all CHD8+/− training cases
from controls. This set of sites, which constitutes the
CHD8+/− DNAm signature, was used for downstream
biological and classification analyses. Importantly, this
CHD8+/− DNAm signature (422 sites) also accurately
classified all CHD8 test case sequence variants (matching in silico predictions) and classified GEO controls
with > 99.3% specificity. This DNAm signature classified
all but one heterogeneous ASD case as clustering with
controls (data not shown), suggesting the need to
increase stringency of the signature for more accurate
classification.
Therefore, we investigated whether the use of a more
stringent filter of statistical significance (q < 0.01 and
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Fig. 2 a, b DNAm signatures identified in whole blood of individuals with 16p11.2del (600 kb risk locus) or CHD8+/−. a Hierarchical clustering and PCA
plot (first 3 principal components labeled) show that 16p11.2del training cases (purple; n = 9) are distinct from age-, sex-matched controls (green; n =
23) at the DNAm signature sites (115 CpG sites; q < 0.05, absolute methylation difference (|Δβ| ≥ 5%). b Hierarchical clustering and PCA plot (first 3
principal components labeled) show that CHD8+/− training cases (orange; n = 7) are distinct from age-, sex-matched controls (green; n = 21) at DNAm
signature sites (103 CpG sites; q < 0.01, |Δβ| ≥ 5%) used for classification. Only a single CpG site overlaps between the 16p11.2del and CHD8+/− DNAm
signatures: cg25970491 (CLTCL1), which is hypomethylated in both CHD8+/− and 16p11.2del cases relative to controls. All data are normalized for
visualization (mean = 0, variance = 1). In heat map, yellow represents high methylation and blue represents low methylation

|Δβ| ≥ 5%) could be used to derive a more specific
DNAm signature. Applying this filter reduced the previously derived DNAm signature to a subset of 103
CpG sites (95 (92.2%) hypomethylated, 8 (7.6%)
hypermethylated) with a |Δβ| range of 5–18%
(Additional file 2: Figure S3; Additional file 3: Table
S7) that was used for classification purposes. Hierarchical clustering and PCA plot demonstrate that at
this set of sites, cases are still distinguished clearly
from controls (Fig. 2b), and that heterogeneous ASD
cases and CHD8 test sequence variants are classified
with even greater precision (Fig. 3c) (discussed in

greater detail in the “Sensitivity and specificity of the
CHD8+/−-specific DNAm signature” section).
Comparison of DNAm signatures with identified DMRs

Using an alternative analytic approach, we evaluated
DMRs to detect regional DNAm differences and to confirm consistent patterns overlapping the significant CpG
sites identified in our DNAm signatures. Significant
DMRs were defined by p < 0.05, |Δβ| ≥ 5% and at least
3 consecutive CpG sites, of which at least one has
already been identified in the 16p11.2del (115 sites) and
CHD8+/− (422 sites) DNAm signature CpG sites
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Fig. 3 a–d Evaluating the sensitivity and specificity of the 16p11.2del and CHD8+/− DNAm signatures. The classification models (details in Ref.
[15]) are represented by the following classification plots: a The classification model based on the 16p11.2del DNAm signature sites (115 sites; q <
0.05, |Δβ| ≥ 5%) accurately classified CHD8+/− signature cases, and independent test cases consisting of CHD8 sequence variants (orange box with
cross) and heterogeneous ASD cases (open gray triangle) as more similar to controls (green C). The model also accurately classified 7 of 9
independent 16p11.2del test cases (solid purple circle) as more similar to 16p11.2del signature cases (open purple circle), demonstrating 100%
sensitivity. Two variants (arrows) correctly received negative classification scores: hatched arrow indicates a mosaic 16p11.2del case (2-0088-003),
solid arrow indicates a 16p11.2del distal to and not overlapping the 600 kb typical deletion region (1-0616-003). b The 16p11.2del DNAm
signature was tested on an independent set of compiled blood control DNAm data (n = 162) extracted from the Gene Expression Omnibus
(GEO) Database. All GEO controls (turquoise C) were properly classified with experimental controls (green C), as distinct from 16p11.2del signature
training cases (open purple circle), demonstrating 100% specificity. c The classification model based on the CHD8+/− DNAm signature sites for
classification (103 sites; q < 0.01, |Δβ| ≥ 5%) accurately classified 16p11.2del signature cases and independent test cases consisting of 16p11.2del
variants (purple circle with cross) and heterogeneous ASD cases (gray triangle) as more similar to controls (green C). The model also accurately
classified 1 of 9 independent CHD8 test cases consisting of sequence variants (solid orange square) as more similar to CHD8+/− signature training
cases (open orange square) (unable to report sensitivity with one positive case, indicated by arrow). Eight variants correctly received negative
classification scores (7 missense, 1 with an in-frame deletion in the last exon of CHD8, not predicted pathogenic). Classifications are in agreement
with in silico predictions. d The CHD8+/− DNAm signature was tested on the same GEO controls (turquoise C) as in b; all but one GEO control
were properly classified with experimental controls (green C), as distinct from CHD8+/− signature cases (open orange square), demonstrating
>99.3% specificity

Siu et al. Clinical Epigenetics

(2019) 11:103

(Additional file 3: Tables S3 and S4). DMRs found in the
case-control comparisons yielded 26 and 70 overlapping
CpG sites with the 16p11.2del and CHD8+/− DNAm signatures, respectively. Representative examples of DMR
bumps that overlap DNAm signature sites are depicted
in Additional file 2: Figure S4.
The 16p11.2del and CHD8+/− DNAm signatures are not
confounded by blood cell type

We have taken blood cell type proportion estimates into
account as a possible confounding factor by including
them as covariates in the derivation of each DNAm signature. To further demonstrate that differences in cell type
proportion do not contribute to the differences identified in
our 16p11.2del and CHD8+/− DNAm signatures, we show
that all normal purified blood cell types from the study by
Reinius et al., 2012 [41] (data available from GEO35069)
are correctly classified as controls by both signatures (similarly applied in Ref. [14, 15]). None of the methylation profiles for any of the specific blood cell types cluster with or
near the signature cases at each respective signature, indicating that cell type-specific methylation profiles are not
driving the differences identified at signature sites. Therefore, our DNAm signatures are not confounded by DNAm
variation associated with blood cell types (Additional file 1;
Additional file 2: Figures S5 and S6).
Sensitivity and specificity of the 16p11.2del-specific
DNAm signature

We used the 16p11.2del DNAm signature to classify 9
additional 16p11.2del test case variants. For these cases,
7 of 9 received positive scores. These 7 cases receiving
positive scores all carried typical 16p11.2del, clustering
closely with signature cases (Fig. 3a; Table 3). Two of 9
cases received negative scores, appearing either on the
diagonal border (2-0088-003) or clustering more closely
with controls (1-0616-003) (Fig. 3a; Table 3). One of
these two intermediate cases is known to be mosaic for
the 16p11.2del (referred to as MM0088-003 in Ref. [32]),
explaining its borderline position. The second case has a
200 kb deletion distal to the typical deletion region.
Thus, our 16p11.2del DNAm signature demonstrates
100% sensitivity, accurately detecting all 7 variants with
typical 16p11.2del. The 16p11.2del signature also accurately classified a larger set of independent GEO control
subjects (n = 162), clustering them closely with controls,
thus demonstrating 100% specificity (Fig. 3b; Additional
file 3: Table S5). All CHD8+/− cases were classified as
negative using the 16p11.2del DNAm signature.
Sensitivity and specificity of the CHD8+/−-specific DNAm
signature

We used the more stringent, 103 CpG site subset of the
CHD8+/− DNAm signature to classify additional CHD8 test
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case sequence variants (n = 13: n = 9 samples using 450K
arrays, n = 4 using EPIC arrays) in order to predict
pathogenicity. These classifications were compared with results from in silico prediction algorithms: PolyPhen-2
(http://genetics.bwh.harvard.edu/pph2/), Mutation Assessor (http://mutationassessor.org), SIFT (http://sift-dna.org),
Mutation Taster (http://www.mutationtaster.org). One test
case (450K) (1-0559-003) received a positive score, classifying it as pathogenic, clustering more closely with the
CHD8+/− training signature cases (Fig. 3c; Table 3). This
case, which has a de novo heterozygous frameshift nonsense mutation in CHD8, was also classified as pathogenic
by Mutation Taster, the only predictor available due to the
nature of the variant. All 8 of the other CHD8 test case variants run on the 450K (including VUS) received negative
scores, classifying as benign and clustering with controls
(Fig. 3c; Table 3). For these 8 CHD8 sequence variants, 5
were missense/synonymous mutations inherited from an
unaffected parent (inheritance unknown for 3 samples)
and one was an in-frame deletion in the last exon. At least
three out of four in silico analyses supported the benign
designation of these CHD8 variants. All but one GEO control sample were classified correctly, clustering with controls, thus demonstrating > 99.3% specificity (Fig. 3d;
Additional file 3: Table S5). Classification of the 4 CHD8
test cases run on the EPIC array was performed using only
the overlapping sites from the 450K DNAm signature (92/
103 sites) (Fig. 4). These 92 sites classified 3 test cases as
pathogenic, clustering more closely with signature cases,
and one VUS as benign, clustering with controls. The 3 test
cases receiving positive scores were all known to have
pathogenic CHD8+/− variants. The one sample classified as
benign was an inherited missense variant, similar to those
450K test cases receiving negative scores. All 16p11.2del
cases were classified as negative using the CHD8+/− DNAm
signature.
All the heterogeneous ASD cases (n = 52) received
negative scores when classified with the 16p11.2del or
CHD8+/− DNAm signature used for classification, and
all clustered with controls (Fig. 3a, c).

Genomic distribution of DNAm signature CpG sites

CpG sites in the 16p11.2del DNAm signature (115 sites)
were found to be significantly enriched in CpG islands,
shelves, shores, promoters, and DNase hypersensitivity
sites (DHS), and depleted in shelves (p < 0.05)
(Additional file 2: Figure S7A). Sites in the 422 probe
CHD8+/− DNAm signature were enriched in islands,
shores, particularly the “south” shores (S_Shore) directly
downstream of CpG islands, differentially methylated regions (DMRs) and DHS, and depleted in shelves and
reprogramming-specific DMRs (RDMRs) (p < 0.05);
whereas the 103 site CHD8+/− DNAm signature used for
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overlap with 1 and 10 SFARI Gene ASD-risk genes, respectively (Fig. 5a). The clathrin, heavy chain-like 1
(CLTCL1) gene was hypomethylated in both signatures.
Cross-tissue functional relevance of the CHD8+/− signature

Fig. 4 Evaluating the sensitivity of the CHD8+/− DNAm signature
using additional CHD8 test cases (EPIC array). Additional
independent test cases consisting of CHD8 sequence variants (n = 4;
orange squares with cross) were run on the EPIC array. Of the 103
sites in the 450K-derived CHD8+/− DNAm classification signature, 92
sites overlapped those of the EPIC array and were thus used to
classify the additional EPIC test cases. One VUS case received a
negative classification score. Three of the four additional CHD8 test
cases were accurately classified as more similar to CHD8+/− signature
training cases (open orange square); these cases were known to
have pathogenic CHD8 variants, demonstrating 100% sensitivity. The
one sample classified as benign was an inherited missense variant,
similar to those 450K test cases receiving negative scores. All other
cases and controls (450K) were accurately classified as in Fig. 3

classification was enriched in shores, particularly in S_
Shore, promoters, and DMRs (Additional file 2: Figure
S7B, C).
Biological significance of the 16p11.2del and CHD8+/−
signatures

Using GREAT 3.0.0, we identified molecular and biological processes potentially relevant to the phenotype
of individuals with 16p11.2del or CHD8+/− using the
differentially methylated CpGs from each respective
DNAm signature. When we examined the 16p11.2del
signature (115 sites), 3 of 5 GO Biological Process
terms with significant enrichment (hypergeometric
FDR q-value < 0.05) appeared in categories related to
immune function (Additional file 3: Table S8). When
we examined the CHD8+/− DNAm signature (422
sites), > 20 terms passed with a more stringent hypergeometric FDR q-value < 0.05 (Additional file 3: Table
S9). The top 20 terms showed enrichment not only in
immune processes, but also in the regulation of inhibitory postsynaptic membrane potential and central nervous system development. Differentially methylated
genes specific to 16p11.2del and CHD8+/− signatures

To examine whether DNAm changes downstream of sequence variants in CHD8 in blood are relevant to neuronal
function, we compared the overlap between genes in the
CHD8+/− DNAm signature to differentially expressed genes
(DEGs) in human CHD8+/− iPSC-derived NPCs and
neurons (48). Differentially expressed genes in NPCs and
neurons overlapped 24 (hypergeometric p value < 0.001)
and 54 (hypergeometric p value < 0.001) of our 247 differentially methylated genes in the DNAm signature (q < 0.05,
|Δβ| ≥ 5%), respectively (Fig. 5b). Furthermore, 6 of these
overlapping genes also overlapped SFARI ASD-risk genes.
More recently, Wang et al. [49] further derived cerebral
organoids from their original CHD8+/− iPSCs. These organoids are composed of GABAergic/glutamatergic neurons,
and radial glia progenitor cells with gene expression profiles that resemble first-trimester telencephalon [49–52].
The CHD8+/− DNAm signature overlapped 14 DEGs
found in the CHD8+/− cerebral organoids (Fig. 5c); 6 of
these overlapped DEGs found in both organoids and
neurons, and 5 of these overlapped DEGs found in both
organoids and NPCs.
Validation of differentially methylated CpG sites with
targeted pyrosequencing

Specific CpG sites were selected from the DNAm signatures for validation by targeted pyrosequencing
(Additional file 2: Figure S4). These sites overlapped a
significant DMR that contained at least two sites within
a single gene. For 16p112del cases, the following CpG
sites were validated: cg00108944, cg23588049 in
GLIPR1L2, cg25983544, and cg06377543 in PSMA8. In
the CHD8+/− group, the following CpG sites were validated: cg09819656, cg15089111 in NPAS3, cg27206976,
and cg04089788 in PLXNB2. In the 16p11.2del sites, an
average gain of methylation (GOM) by 14.5% and 13% at
cg00108944 and cg23588049 in GLIPR1L2, respectively,
and loss of methylation (LOM) by 7.4% and 10.5% at
cg25983544 and cg06377543 in PSMA8, respectively
were confirmed by our pyrosequencing analysis (p <
0.005). In the CHD8+/− sites, an average GOM by 17%
and 18.8% at cg09819656 and cg15089111 in NPAS3, respectively, and LOM by 11.4% and 18.9% at cg27206976
and cg04089788 in PLXNB2, respectively, were confirmed (p < 0.005). The correlation between methylation
β values from the 450K array and % methylation values
obtained through pyrosequencing were examined and
were found to be highly concordant (r = 0.8524)
(Additional file 2: Figure S8).
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Fig. 5 Biological and cross-tissue functional significance of differentially
methylated genes. a Differentially methylated genes associated with the
16p11.2del and CHD8+/− DNAm signatures (q < 0.05, |Δβ| ≥ 5%) and the
DNAm signature overlap with known ASD-risk genes (SFARI Gene). A
single SFARI gene, clathrin heavy chain like 1 (CLTCL1), is significantly
hypomethylated in both groups. An independent set of 9 SFARI genes
are differentially methylated in the CHD8+/− DNAm signature. b Our
findings are further corroborated by an independent study (48) showing
that CHD8+/− human iPSC-derived neuronal precursor cells (NPCs) and
differentiated neurons result in differentially expressed genes that
overlap with some of the differentially methylated genes in CHD8+/−
DNAm signature, including known ASD-risk genes (SFARI Gene), and c
another study (49) showing that cerebral organoids derived from the
iPSCs in b also have differentially expressed genes that overlap our
CHD8+/− DNAm signature.

Discussion
One of the greatest challenges of epigenetic research in
ASD is the degree of etiologic and phenotypic heterogeneity. This study uniquely demonstrates that investigating
homogeneous subgroups of individuals with genomic alterations at ASD-risk loci involving epigenes enables the
identification of distinct functionally and biologically relevant DNAm signatures. Previously, evaluations of DNAm
in individuals with ASD have focused on heterogeneous
ASD cases in different tissue types using a variety of different methods. These studies of modest sample sizes (n <
50) have identified few, mostly non-overlapping DNAm
alterations of small magnitude [24, 26–29, 31].
Heterogeneous ASD cases, when compared with controls, did not identify significant (i.e., corrected for multiple testing) differentially methylated sites, paralleling
the aforementioned outcomes of DNAm studies in ASD
[24, 26–31]. We expect that the identification of significant epigenetic differences in such a mixed cohort will
require large numbers (> 1000) of ASD cases. We therefore undertook a novel alternative approach to identifying etiologically relevant epigenetic alterations in ASD.
In contrast to the current literature, we sought to reduce
genetic and epigenetic heterogeneity by focusing analyses on groups of individuals with genomic alterations
involving epigenes that confer an increased risk for ASD.
We show that a relatively small number (< 10) of genetically homogeneous cases can be clearly distinguished from
both a heterogeneous ASD group and neurotypical controls based on DNAm. In the future, these findings will
need to be replicated using larger cohorts of cases with a
wider range of risk-associated variants. Given the expected
genomic heterogeneity for ASD, we did not expect that our
heterogeneous cohort of ASD patients would contain any
individuals with either 16p11.2del or CHD8+/− pathogenic
variants as each of these individually account for < 1% of
all ASD cases. We detected consistent patterns of DNAm
alterations in the 16p11.2del and CHD8+/− blood DNAm
signatures by identifying overlapping DMRs. In addition,
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we validated the top differentially methylated CpG sites in
the DNAm signatures by targeted bisulfite pyrosequencing.
We demonstrate that our DNAm signatures are robust,
overcoming potential confounding factors such as sex, age,
blood cell type proportions, and technical variation, illustrated by our classification of a large number of independently assessed GEO control blood DNAm samples. Some
additional confounding factors to consider include ethnicity and environmental exposures such as medications,
prenatal vitamins, and smoking. Data for these parameters
were not collected consistently across our cases or controls, precluding us from incorporating these factors into
our models. However, given that our signatures yielded
100% sensitivity and > 99% specificity for both signatures,
despite a wide variety of potentially confounding variables,
we expect that our signatures are robust enough to overcome these additional confounders. Further, we were able
to demonstrate cross-platform applicability of our
CHD8+/− DNAm signature derived on the 450K array.
Using this signature, we accurately classified 4 CHD8 sequence variant test cases that were run on the EPIC array.
It is important to recognize that DNAm signatures are
dynamic; their stability and robustness depend on the size
and composition of the group of signature cases used to
derive the signature. DNAm signatures can be optimized
in various ways depending on the specific purposes for
which they are to be utilized. For example, one signature
may provide more information for the examination of
underlying biological pathways of disease, whereas classification of sequence variants in a clinical diagnostic setting
may require a more refined signature to optimize sensitivity and specificity. DNAm signatures can be further optimized to reduce type I error inflation, which may
confound the performance of a signature in a classification
model (see Additional file 1). Although we were only able
to test our signatures on a small group of test cases, we
were able to demonstrate 100% sensitivity. Refining a
signature for clinical diagnostic application will require a
larger discovery cohort with a wider range of variant types
and genomic locations (e.g., alterations across different
functional domains) to improve classification performance
and to better understand their impact on pathogenicity
and functional consequences.
The identification of the 16p11.2del and CHD8+/−
DNAm signatures highlights both the scientific relevance
and the potential for clinical utility. Highly sensitive and
specific genome-wide DNAm signatures have the potential
to be used to identify individuals with pathogenic variants
among groups of heterogeneous ASD cases, an approach
currently in development for molecular diagnostics. As
well, our DNAm signatures are able to facilitate the interpretation of VUS of the respective CNV or epigene variants
detected using sequencing/array-based diagnostics. This
particular application underscores the potential clinical
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utility of this molecular classification system beyond simply
genotyping using NGS technologies. Given that there are
already gene-specific panels available to test for variants in
ASD-risk populations, we propose that in the future, a parallel panel could be used as a complementary second-tier
diagnostic test that would employ various ASD riskspecific DNAm signatures. Finally, differentially methylated
genes that constitute the downstream genomic targets of
ASD-associated CNVs and sequence variants in epigenes
elucidate the biological and molecular pathophysiology of
ASD and identify potential therapeutic targets. Expanding
this work in the future could also lead to the identification
of biomarkers for earlier prediction of neurodevelopmental
outcomes, which would be of tremendous value given the
variable penetrance of ASD with each ASD-risk locus. Although our current study does not have sufficient statistical
power to accomplish this, the future study of large numbers of cases with 16p11.2del and CHD8 sequence variants
in conjunction with deep clinical phenotyping may enable
the identification of more refined epigenotype-phenotype
correlations. Further investigation will also be required to
better understand the impact of altered methylation on
downstream targets for each DNAm signature in a cell
type-, tissue-, and developmental time-specific manner.
Genes and pathways relevant to the clinical phenotypes
of individuals with 16p11.2del or CHD8+/− are elucidated
by their respective DNAm signatures. Interestingly, the
single gene, CLTCL1, found to be similarly hypomethylated in both the 16p11.2del and CHD8+/− signatures, is
found in the 22q11.2 deletion syndrome (22qDS; OMIM#
611867) deletion region. 22qDS is associated with a range
of clinical phenotypes, but notably, several neurodevelopmental (ASD, ADHD), and neuropsychiatric (schizophrenia) outcomes [53]. In the 16p11.2del signature, multiple
sites in GLI pathogenesis-related 1 like 2 (GLIPR1L2; 8
hypermethylated sites, |Δβ| > 10%) and proteasome subunit alpha 8 (PSMA8; 3 hypomethylated sites, |Δβ| > 8%)
were found to be significantly differentially methylated.
GLIPR1L2 and PSMA8 have not previously been associated with ASD, but encode proteins that function in
immunity and histone degradation, respectively. The
CHD8 gene is known to negatively regulate beta catenin
(CTNNB1) and WNT pathways, both important for
development and growth, through the direct interaction
between CHD8 and CTNNB1. Our study extends the
current knowledge of downstream targets regulated by
CHD8 through its role as a chromatin remodeler. The
genes with the greatest differential DNAm in our
CHD8+/− signature highlight pathways that are relevant to
the pathophysiology of ASD. These include Plexin B2
(PLXNB2; 4 hypomethylated sites, |Δβ| > 12%) and neuronal PAS domain protein 3 (NPAS3; 2 hypermethylated
sites, |Δβ| > 15%), both of which are expressed in the
brain during embryonic development [54, 55]. PLXNB2
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encodes a transmembrane receptor protein that
participates in axon guidance and is required for normal
embryonic development/differentiation and migration of
neuronal cells during brain corticogenesis [54, 56]. PLXNB2
is deleted in the Phelan-McDermid, 22q13.3 deletion
syndrome region, which is associated with dysmorphic
features, neurologic deficits and ASD. This overlap could
suggest that epigenetic dysregulation of shared biological
pathways across disorders is reflected in overlapping clinical
features. This has been demonstrated in the case of
CHARGE and Kabuki syndromes, two clinically distinct
syndromes sharing a subset of phenotypes [14]; each
syndrome has a distinct DNAm signature, each of which
also includes some overlapping sites affecting genes involved in pathways relevant to specific concordant syndromic features. Mouse models with Plxnb2 deletions
are perinatal lethal and have abnormal cerebellar development, reflecting the critical role of the gene in neurodevelopment [56]. NPAS3, expressed by GABAergic
interneurons, has been shown to be an important transcription factor during neurogenesis; chromosomal aberrations encompassing this gene are associated with
schizophrenia and mental retardation [55, 57]. The
finding that immune-related genes are enriched in both
the 16p11.2del and CHD8+/− signatures supports recent
data highlighting contributions of altered immune function to ASD pathophysiology [58–60]. Individuals with
16p11.2del or CHD8+/− do not demonstrate consistent
immune phenotypes; however, the dysregulation of immune genes could mediate changes in early embryogenesis that may affect neurogenesis and subsequently
ASD risk. Immune dysregulation likely only contributes
to the pathophysiology of disease for a subset of individuals with ASD, rather than all individuals. Importantly, the identification of these pathways could help to
identify targets for potential drug therapies and facilitate more individualized interventions.
We searched for overlap between differentially methylated sites in our 16p11.2del and CHD8+/− blood DNAm
signatures and previous DNAm studies of ASD. Two
differentially methylated genes (DNPEP, RAD50) in the
CHD8+/− signature overlapped with the single 450K array
study of DNAm in the blood of individuals with ASD [29].
Differentially methylated genes identified in the brain
regions Brodmann areas (BA) 10 and 24 of the cerebral
cortex (27) overlap a number of differentially methylated
DNAm signatures genes in our study: 16 genes in the
16p11.2del signature, 51 genes in the CHD8+/− signature in
BA10 and 22 genes in the 16p11.2del signature, and 82
genes in the CHD8+/− signature in BA24. A more recent
study also examining DNAm in the postmortem brain (prefrontal and temporal cortices, cerebellum and cross-cortical
analysis) in individuals with idiopathic ASD identified
region-specific significant differentially methylated sites
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[30]. Although none of our signature sites overlapped those
identified in Wong et al. [30], both studies identified pathway enrichment in immune and neuronal processes, which
were found using two different analytical pipelines (GREAT
in our study, weighted gene co-methylation network analysis in Ref. [30]). These data suggest that certain DNAm alterations found in blood are likely to be reflected in the
brain or in genes of related biological pathways, which is of
particular relevance for research in neurodevelopmental
disorders (NDDs). Although ASD is an NDD with heterogeneous etiology(ies) and phenotypes, where the brain is
undoubtedly an important organ to study, the pathophysiology of ASD is still unclear, affecting multiple systems
(e.g., gastrointestinal) and pathways (e.g., metabolic, immune). DNAm in blood also reflects environmental exposures (e.g., gestational alcohol exposure). It is important to
distinguish between the different potential utilities of
DNAm signatures. From a biomarker perspective, whether
genes identified by a DNAm signature in blood can be
causally linked to the disease phenotype is less important
than identifying DNAm marks that predict the phenotype
in a stable, sensitive, and specific manner. From a biological
perspective, an increasing number of studies do in fact
demonstrate an intersection between DNAm patterns in
the blood and brain using similar genome-wide assessment
platforms [61–63], which may help to elucidate underlying
pathophysiological mechanisms. Our findings in blood are
further corroborated by an independent study [48, 49]
showing that CRISPR/Cas9-mediated creation of CHD8+/−
human iPSC-derived NPCs, differentiated neurons, and
cerebral organoids results in differentially expressed genes
that overlap with some of the differentially methylated
genes in our CHD8+/− DNAm signature (Fig. 5b, c), including known ASD-risk genes (SFARI Gene).
It is possible that epigenetic marks other than DNAm at
CpG sites, such as 5-hydroxymethylcytosine (5-hmC),
may also demonstrate differences between individuals
with ASD and neurotypical controls. 5-hmC is abundant
in the brain and not in the blood [64, 65] and is yet to be
explored with respect to ASD in humans, although mouse
models of ASD have demonstrated genome-wide differences [66]. A potential role for altered histone acetylation
in ASD has been demonstrated in a recent human brain
histone acetylome study [67]. Animal studies have more
extensively investigated the effects of in utero exposure to
a histone deacetylase inhibitor, valproic acid, on autisticlike behavioral and cognitive outcomes in offspring [68–
70]. Further research exploring downstream molecular
functional studies such as gene and protein expression are
also necessary to fully understand the functional consequences of either the ASD-associated CNV or gene variants of interest in our study. Nevertheless, our DNAm
signatures represent novel DNA biomarkers in an easily
accessible tissue (blood) that are more stable than histone
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marks and present novel clinical diagnostic applications.
Our DNAm signatures include alterations in genes that
may be important for understanding the underlying
pathophysiology of ASD and demonstrate parallel relevance in gene expression profiles within cell types representative of the brain.

Conclusions
In summary, we present a novel approach that enhances
the detection of epigenetic dysregulation in ASD etiology. Our successful identification of highly sensitive
and specific CNV/gene mutation-specific DNAm signatures provides significant opportunities for clinical impact, offering more precise ASD subgroup molecular
classification with the potential for developing diagnostic
and predictive biomarkers. Our investigations provide a
more comprehensive understanding of the molecular
landscape underlying genetically homogeneous groups of
ASD, illustrating the convergence of epigenetic and genetic mechanisms. These findings will also help to further
elucidate the molecular pathophysiology of ASD and facilitate the identification of novel therapeutic targets to
support precision therapies for individuals with ASD.
Additional files
Additional file 1: Supplementary information. (DOCX 18 kb)
Additional file 2: Figure S1. Data analysis flowchart. Outline of the
training cohorts and analysis pipeline used to derive DNAm signatures
and test cohorts (independent samples), on which the DNAm signatures
were tested. Figure S2. Identification of differentially methylated CpG
sites when comparing 16p11.2del signature cases with age-, sex-matched
controls. Significant sites for the DNAm signature for 16p11.2del represented by the overlap from limma regression and Mann Whitney U analysis are shown. Each volcano plot represents the distribution of
significant sites at various statistical parameters (y-axis is negative log qvalue, Benjamini-Hochberg corrected) and Δβ differences (x-axis is the
average difference in DNAm between 16p11.2del and controls). Red horizontal line represents q < 0.05, red vertical lines represent |Δβ| ≥ 5%. Figure S3. Identification of differentially methylated CpG sites when
comparing CHD8+/− signature cases with age-, sex-matched controls. Significant sites for the DNAm signature for CHD8+/− represented by the
overlap from limma regression and Mann Whitney U analysis are shown.
Each volcano plot represents the distribution of significant sites at various
statistical parameters (y-axis is negative log q-value, Benjamini-Hochberg
corrected) and Δβ differences (x-axis is the average difference in DNAm
between CHD8+/− and controls). Red horizontal line represents q < 0.05,
red vertical lines represent |Δβ| ≥ 5%. Figure S4. Targeted sodium bisulfite pyrosequencing of selected 16p11.2del and CHD8+/− DNAm signature
CpG sites overlapping differentially methylated regions (DMRs). Specific
CpG sites from our DNAm signatures that overlapped DMRs found using
bump hunting were selected for targeted sodium bisulfite pyrosequencing validation in signature cases and age-, sex-matched controls. In the
16p11.2del group, the following CpG sites were validated: A) cg00108944
and cg23588049 in GLIPR1L2 showing a gain of methylation, B)
cg25983544 and cg06377543 in PSMA8 showing a loss of methylation. In
the CHD8+/− group, the following CpG sites were validated: C)
cg09819656 and cg15089111 in NPAS3 showing a gain of methylation, D)
cg27206976 and cg04089788 in PLXNB2 showing a loss of methylation.
Upper graphs in each panel depict mean methylation (y-axis) over each
DMR (x-axis, position of CpG sites along the chromosome) for the
16p11.2del (purple), CHD8+/− (orange) and control (green) groups. Box
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plots represent median methylation at the specific CpG sites indicated
with min/max whiskers. Figure S5. Correlation of pyrosequencing and
array data. We demonstrate that there is high correlation (r = 0.8524) between the bisulfite pyrosequencing validation % methylation and array
methylation beta (β) values. Data include all samples run at all 8 of the
specific CpG sites assayed for validation. Figure S6. Comparison of the
16p11.2del DNAm signature with blood cell type composition. Blood cell
type DNAm data was extracted from Reinius et al. [41] (GEO series
GSE35069) representing whole blood, peripheral blood mononuclear
cells, granulocytes and isolated cell populations (CD4+ T cells, CD8+ T
cells, CD56+ NK cells, CD19+ B cells, CD14+ monocytes) from 6 different
control individuals. Blood cell type data was combined with our signature
cases and control data using only the CpGs from the 16p11.2del-specific
DNAm signature. The PCA plot demonstrates that the 16p11.2del signature is independent of blood cell type composition where signature cases
remain separated from controls cases (whole blood and purified blood
cell types). Abbreviations: PBMC peripheral blood mononuclear cells; WB
whole blood. Figure S7. Comparison of the CHD8+/− DNAm signature
with blood cell type composition. Blood cell type DNAm data was extracted from Reinius et al. (41) (GEO series GSE35069) representing whole
blood, peripheral blood mononuclear cells, granulocytes and isolated cell
populations (CD4+ T cells, CD8+ T cells, CD56+ NK cells, CD19+ B cells,
CD14+ monocytes) from 6 different control individuals. Blood cell type
data was combined with our signature cases and control data using only
the CpGs from the CHD8+/−-specific DNAm signature. The PCA plot demonstrates that the CHD8+/− signature is independent of blood cell type
composition where signature cases remain separated from controls cases
(whole blood and purified blood cell types). Abbreviations: PBMC peripheral blood mononuclear cells; WB whole blood. Figure S8. Genomic distribution of DNAm signature CpG sites. Bar charts representing the
genomic distribution of CpG sites in the 16p11.2del (A) and CHD8+/−-specific DNAm signatures (B, C [classification signature]), according to Illumina 450K array annotations. In mammalian cells, DNAm occurs
predominantly on cytosines located in CpG dinucleotides. CpG islands
refer to regions that are especially CpG-rich. Specific locations of CpGs
relative to the CpG island can be denoted as “shores” and “shelves”. A
shore is 0–2 kb from a CpG island, a shelf is 2–4 kb from a CpG island. N
refers to regions upstream (5′) and S refers to regions downstream (3′) of
a CpG island. We compared the distribution of the CpGs between each
respective variance filtered dataset with each signature training case
group for the regulatory feature group, relation to CpG island and other
functional categories such as overlapping enhancer region, DNase hypersensitive sites (DHS) and type of differentially methylated regions (Reprogrammed DMR (RDMR), cancer-specific DMR (cDMR), other DMR) in
addition to relation to RefSeq group annotation. N refers to north and S
refers to south. Asterisk denotes significant enrichment or depletion by
hypergeometric test comparison (p < 0.05). Figure S9. The quantile-quantile
plot showing the log-transformed distributions of limma regression p-values
associated with the DNAm differences in CHD8+/− cases compared to
matching controls. The results are shown before (left) and after (right) correction by the BACON method, with inflation patterns evident in both cases.
Figure S10. The quantile-quantile plot showing the log-transformed distributions of limma regression p-values associated with the DNAm differences
in 16p11.2del cases compared to matching controls. The results are shown
before (left) and after (right) correction by the BACON method, with inflation
patterns evident in both cases. (PPTX 2477 kb)
Additional file 3: Table S1. Demographic information for heterogeneous
ASD cases and age- and sex-matched neurotypical controls. Table S2. Number of probes removed and remaining for analysis following quality control.
Table S3. List of overlapping DMRs for 16p11.2del. Table S4. List of overlapping DMRs for CHD8+/−. Table S5. List of samples extracted from GEO database and respective 16p11.2del and CHD8+/− signature scores for specificity
analysis. All sample data are from blood and from individuals with known
ages < 50 years old. Table S6. List of significant (q < 0.05, |Δβ| ≥ 5%) sites in
16p11.2del DNAm signature. Table S7. List of significant (q < 0.05, |Δβ| ≥
5%) sites in CHD8+/− DNAm signature. Table S8. GO Biological Process enrichment terms following GREAT enrichment analysis of differentially methylated genes in 16p11.2del DNAm signature. Table S9. GO Biological
Process enrichment terms following GREAT enrichment analysis of differentially methylated genes in CHD8+/− DNAm signature. (XLSX 156 kb)
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